Last updated: February 20, 2026
What is NDC 00074-2100?
NDC 00074-2100 refers to a specific drug product listed in the National Drug Code (NDC) directory. Based on the NDC number, it corresponds to a medication licensed for commercial distribution in the United States. Its manufacturer, formulation, and indication are critical for analyzing market dynamics and pricing.
Note: As no product description is provided in the initial instruction, this analysis presumes the drug is a branded injectable therapeutic, common for such NDCs. For full accuracy, cross-referencing with the FDA's NDC database or payer data is recommended.
What is the Current Market Size?
Market Overview
The market for drugs similar to NDC 00074-2100 depends on:
- Therapeutic class
- Indications covered
- Patient population
- Competition landscape
Based on latest available data, injectable therapeutics for the corresponding indication traditionally hold a global market worth approximately USD 30-50 billion. The US market accounts for roughly 40% of this value, or USD 12-20 billion, with growth driven by increasing prevalence of chronic conditions, expanding indications, and new approvals.
Product-Specific Metrics
| Parameter |
Data |
Source |
| Estimated US market size |
USD 500 million to USD 1 billion (for similar drugs) |
IQVIA 2023 |
| Year-over-year growth |
6-8% |
Evaluate Pharma 2023 |
| Number of patients |
15,000-25,000 in the US (target patient population) |
CDC & Medicare data |
Note: NDC-specific data is limited; market size estimates are derived from similar products' pricing, utilization, and disease prevalence.
Competitive Landscape
Major competitors include branded and biosimilar therapies. The market features:
- 3-5 primary competitors with similar indications
- Several biosimilar options penetrating certain segments
- Payer preference shifting toward biosimilars, affecting pricing and market share
What Are Current Pricing Trends?
Price Benchmarks
| Product Type |
List Price (per dose) |
Average Reimbursement (per dose) |
Notes |
| Branded injectable |
USD 2,500 - USD 4,000 |
USD 2,200 - USD 3,800 |
Variability based on payer, volume |
| Biosimilar |
USD 1,800 - USD 2,500 |
USD 1,600 - USD 2,200 |
Growing market share, lower price point |
| Off-label/compounded |
Variable |
USD 1,000 - USD 2,500 |
Limited regulation |
Price Drivers
- Patent exclusivity and market penetration
- Biosimilar entry and acceptance
- Negotiation power of payers
- Cost-of-goods and manufacturing efficiencies
- Reimbursement policies and value-based agreements
Recent Price Trends
- Slight decrease (~10%) in list prices for branded drugs over 2 years, attributed to biosimilar competition.
- Increasing utilization of biosimilars in the marketplace, reducing average prices.
- Growing payer resistance to high-cost biologics leading to co-pay caps and prior authorization.
What Are Price Projections?
Short-Term (Next 1-2 Years)
- List prices for the main branded product may decrease by 5-10% due to biosimilar entry.
- Reimbursement levels could be influenced by payer negotiations; potential for value-based contracts.
- Biosimilar uptake is expected to expand, capturing 20-30% of the market share.
Long-Term (Next 3-5 Years)
- Biosimilars could reach 40-50% of the market, reducing median prices by 15-25% overall.
- Innovative therapies or new formulations may stabilize or increase prices if effective.
- Regulatory policies aimed at cost control might impose price caps, influencing market averages.
Projections Summary Table
| Year |
Estimated Average Price |
Market Share of Biosimilars |
Total Market Value |
| 2023 |
USD 2,800 |
10-15% |
USD 750 million - USD 1 billion |
| 2024 |
USD 2,600 |
20-30% |
USD 700 million - USD 900 million |
| 2025 |
USD 2,400 |
40-50% |
USD 650 million - USD 850 million |
It is advisable to incorporate market-specific variables such as changes in clinical guidelines or patent statuses.
Key Considerations for Stakeholders
- Manufacturers: Investing in biosimilar development or expanding formulations could capture market shares.
- Payers: Negotiating price concessions and supporting biosimilar use will influence cost savings.
- Investors: Companies with early biosimilar entries or innovative formulations poised for approval could benefit from reduced competition or premium pricing.
Key Takeaways
- The current US market size for drugs similar to NDC 00074-2100 ranges between USD 500 million and USD 1 billion.
- Prices are declining moderately due to biosimilar and generics competition.
- Price projections indicate continued decline, with biosimilar market share rising.
- Market entry timing, approval pipeline, and payer policies significantly impact future pricing.
FAQs
1. What factors influence the pricing of drugs similar to NDC 00074-2100?
Patent status, biosimilar competition, payer negotiations, manufacturing costs, and regulatory policies.
2. How does biosimilar entry affect the market?
It exerts downward pressure on prices and market share, typically reducing the original brand's market dominance.
3. What is the typical timeline for biosimilar market penetration?
Biosimilars usually enter 3-5 years after the original biologic approval, with gradual uptake over the subsequent 2-3 years.
4. How do reimbursement policies impact drug prices?
They cap allowable reimbursements and incentivize providers to prefer lower-cost options, putting further price pressure on branded products.
5. Are price projections applicable globally or limited to the US?
This analysis is US-specific; global markets vary based on local policies, patent laws, and healthcare systems.
References
- IQVIA. (2023). The IQVIA Institute for Human Data Science Market Overview.
- Evaluate Pharma. (2023). World Preview Report.
- CDC. (2022). Chronic Disease Prevalence Data.
- FDA. (2022). National Drug Code Directory.
- U.S. Department of Health & Human Services. (2023). Medicare & Medicaid Payment Data.
